Wugen secures $172M series B to advance memory NK, CAR T cell therapies
Financing to support clinical studies of multiple allogeneic programs
After adding memory NK cells to its cell therapy tool kit last year, Wugen has raised $172 million in a series B round led by Abingworth and Tybourne Capital to advance multiple off-the-shelf therapies for cancer.
Wugen Inc. launched in 2018 to develop CAR T cell therapies, but broadened its scope last year to include memory NK cells after in-licensing the technology from Washington University in St. Louis. ...